/
LIMN
$0.13+$0.04 (+38.16%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.3M
67M shares
52-week range
$0.10 – $4.85
1% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-9.92
Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
liminatuspharma.com- Employees
- 1
- IPO / List date
- May 1, 2025
- HQ
- CERRITOS, CA
Held by traders on TradeandTell
No one on the platform currently holds LIMN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in LIMN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LIMN yet.
